Imetelstat Sodium - NCI - National Cancer Institute
Imetelstat sodium works by blocking the activity of an enzyme called telomerase, which is found at high levels in cells that divide rapidly, including cancer cells. Blocking this enzyme keeps …
Geron Announces FDA Approval of RYTELO™ (imetelstat), a
Jun 6, 2024 · About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor …
Imetelstat (Rytelo™) - OncoLink
Jun 16, 2024 · Imetelstat (Rytelo™) is a telomerase inhibitor.How To Take Imetelstat Imetelstat is given intravenously (into a vein). The amount given and schedule are based on your size. You …
Rytelo: Uses, Dosage, Side Effects, Warnings - Drugs.com
Jul 16, 2024 · Rytelo (imetelstat) is an injectable telomerase inhibitor that may be used to treat adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion …
Imetelstat (Rytelo): a promising treatment for adults with lower …
The injectable oligonucleotide telomerase inhibitor Imetelstat is the first drug of its kind, as it functions by attaching to the telomerase enzyme, preventing telomere binding and blocking its …
Oncology Drug Reference Sheet: Imetelstat - ons.org
Mar 18, 2025 · In June 2024, imetelstat (Rytelo™) became the first telomerase inhibitor approved by the U.S Food and Drug Administration (FDA). Imetelstat treats low- to intermediate-risk …
Imetelstat: a new addition to the therapeutic landscape of lower …
Jan 30, 2025 · Imetelstat is an oligonucleotide telomerase inhibitor recently approved by the US Food and Drug Administration for adults with lower-risk myelodysplasia wh
FDA approves imetelstat for low- to intermediate-1 risk …
On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk ...
Why RYTELO (imetelstat) | RYTELOHCP
INDICATION RYTELO® (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia …
Clinical - Imetelstat
Imetelstat for treatment of myelofibrosis J. Mascarenhas et al (tandfonline.com, 10 Dec 2016) Areas covered: The pre-clinical rationale for the use of the telomerase inhibitor, imetelstat, in …